These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 28976446)
1. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer. Giuliani J; Bonetti A Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446 [TBL] [Abstract][Full Text] [Related]
2. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Edwards SJ; Barton S; Thurgar E; Trevor N Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481 [TBL] [Abstract][Full Text] [Related]
3. Treatment of recurrent ovarian cancer. Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464 [TBL] [Abstract][Full Text] [Related]
4. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893 [TBL] [Abstract][Full Text] [Related]
5. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Sehouli J; Alfaro V; González-Martín A Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221 [TBL] [Abstract][Full Text] [Related]
6. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Havrilesky LJ; Secord AA; Kulasingam S; Myers E Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of trabectedin in treating ovarian cancer. Teplinsky E; Herzog TJ Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689 [TBL] [Abstract][Full Text] [Related]
8. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562 [TBL] [Abstract][Full Text] [Related]
9. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. López-Guerrero JA; Romero I; Poveda A Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617 [TBL] [Abstract][Full Text] [Related]
11. Trabectedin for the treatment of relapsed ovarian cancer. Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655 [TBL] [Abstract][Full Text] [Related]
12. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Ojeda B; de Sande LM; Casado A; Merino P; Casado MA Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial. Fisher M; Gore M Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284 [TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer. Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683 [TBL] [Abstract][Full Text] [Related]
16. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470 [TBL] [Abstract][Full Text] [Related]
17. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380 [TBL] [Abstract][Full Text] [Related]
18. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332 [TBL] [Abstract][Full Text] [Related]
19. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479 [TBL] [Abstract][Full Text] [Related]
20. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]